AxoGen, Inc. to Present at the Wedbush PacGrow Healthcare Conference
July 31 2017 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that Karen Zaderej, President and Chief
Executive Officer, will present at the Wedbush PacGrow Healthcare
Conference in New York City, NY, at the LeParker Meridien. The
presentation is scheduled for Tuesday, August 15, 2017 at 8:35 a.m.
ET.
The presentation will be webcast live and can be
accessed through the Investors page at www.axogeninc.com. For those
not available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.axogeninc.com.
About AxoGenAxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen is the only company focused specifically on the
science, development and commercialization of technologies for
peripheral nerve regeneration and repair. We are passionate about
restoring nerve function and quality of life to patients with
peripheral nerve injuries by providing innovative, clinically
proven and economically effective repair solutions for surgeons and
health care providers. Peripheral nerves provide the pathways for
both motor and sensory signals throughout the body. Every day,
people suffer traumatic injuries or undergo surgical procedures
that impact the function of their peripheral nerves. Damage to
a peripheral nerve can result in the loss of muscle or organ
function, the loss of sensory feeling, or the initiation of
pain.
AxoGen's portfolio of products includes Avance®
Nerve Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix (ECM) coaptation aid for tensionless
repair of severed nerves, AxoGuard® Nerve Protector, a porcine
submucosa ECM product used to wrap and protect injured peripheral
nerves and reinforce the nerve reconstruction while preventing soft
tissue attachments, and Avive® Soft Tissue Membrane, a
minimally processed human umbilical cord membrane that may be used
as a resorbable soft tissue covering to separate tissue layers and
modulate inflammation in the surgical bed. Along with these core
surgical products, AxoGen also offers AcroVal™ Neurosensory &
Motor Testing System and AxoTouch™ Two-Point Discriminator. These
evaluation and measurement tools assist health care professionals
in detecting changes in sensation, assessing return of sensory,
grip, and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom, and several other
European and international countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
"forward-looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "projects," "forecasts,"
"continue," "may," "should," "will," and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2017
guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024